US-based cancer intelligence company C2i Genomics has introduced its C2inform minimal residual disease (MRD) test in Europe.

The device obtained CE-IVD marking in the EU and the UK and completed several clinical trials in various cancer centres in the US, Singapore and Europe.

Claimed to be the first CE marked software-as-a-medical-device MRD test, C2inform is a simple procedure for in-house by any pathology lab or genomic cancer lab to deliver testing closer to the patient.

The test allows personalised, cost-effective, and globally accessible cancer treatment monitoring and analytics for a wide range of solid cancers.

It uses whole-genome sequencing and artificial intelligence on a 3-4mL blood sample to aid speedy and accurate cancer detection, illness progression monitoring, and therapy efficacy evaluation.

The firm said the MRD test will help to customise the treatment plan and support the development of more effective cancer treatments.

C2inform involves less lab operating complexity, avoiding the need for the development of a patient-specific assay. It provides a speedy and high throughput option for cancer patients.

The European regulatory CE marking indicates validates C2inform’s high safety, health, and environmental protection standards and will further allow for commercial sale to the labs.

C2i Genomics CEO and co-founder Asaf Zviran said: “The last year has been incredibly exciting as we’ve solidified multiple global partnerships to expand our distributed diagnostic model.

“With several strategic partnerships throughout Europe and now with the CE Mark registration, we’re eager to scale our C2inform test to bring whole genome cancer detection and monitoring across Europe.

“As C2i continues to expand commercial availability our goal at our core is to continue advancing better patient outcomes and more precise oncology treatments.”

The C2inform test is said to be the first product to be made from C2intelligence cloud-based platform.